By Lyndsay Gregerson, RD, CDCES
Principal Clinical Territory Manager, Wisconsin South
Insulin pumps help patients optimize their diabetes management in various ways. Insulin pumps only use rapid-acting insulin. The action of rapid-acting insulin is more predictable and reproducible than long-acting insulin. The continuous infusion of basal—the small amounts of rapid-acting insulin—are more easily absorbed than long-acting insulin.1 Using an integrated continuous glucose monitor (CGM) allows automated features to be used.
Medtronic MiniMed™ has a 40-year history, including the first integrated pump and continuous glucose monitoring (CGM) system, first in automating insulin delivery, and we are committed to continuing to transform diabetes care together for greater freedom and better health!
As a result of Medtronic’s innovation, your patients could have any of four insulin pump models: Paradigm™ series, the MiniMed™ 630G, MiniMed™ 670G, or MiniMed™ 770G. At present time, the MiniMed™ 630G and MiniMed™ 770G systems are available for new customers or patients who are upgrading. Following is a closer examination of the 630G and 770G systems.
With both the MiniMed™ 630G and MiniMed™ 770G systems, the fundamental basics of insulin pump therapy stand true, and the supplies are interchangeable. The key differences between the two are the level of automation and the regulatory approval. Specifically, the MiniMed™ 630G is FDA approved for use by people living with type 1 and type 2 diabetes. The MiniMed™ 770G system is approved for those living with type 1 diabetes. For questions regarding off-label use please contact the Medtronic Diabetes Office of Medical Affairs at: firstname.lastname@example.org.
The MiniMed™ 630G uses manually programmed basal rates, while offering unique bolusing options. Besides the availability of the Bolus Wizard feature™ (using carb grams or exchanges), the MiniMed™ 630G can be programmed with up to seven preset bolus selections, which is accessible in the bolus menu or through the remote function on the Contour® Next Link meter. The opportunity to integrate with CGM is available (Guardian™ Sensor 3), with the option to have automation to help protect against hypoglycemia through SmartGuard™ Suspend on Low (programmable for 60-90 mg/dL.)
The MiniMed™ 770G system can be used in 3 different ways offering different levels of automation. While in Manual Mode, SmartGuard™ Suspend on low or SmartGuard™ Suspend before low can be used, while Auto Mode adapts basal delivery to sensor glucose reading every 5 minutes targeting 120 mg/dL. In addition, the MiniMed™ 770G has Bluetooth connectivity (MiniMed™ Mobile app) to offer automatic CareLink™ uploads, discreet viewing of pump and CGM data, along with notifications to up to 5 care partners through their own phone (CareLink™ Connect app). MiniMed ™770G is also enabled to accept future software upgrades. For customers who have already or will be purchasing the MiniMedTM 770G, they will get access to our next technology when available at no cost through October 27, 2022*.
The MiniMedTM 780G system and GuardianTM sensor 4 have been submitted to the FDA for approval. This submission is the next step in the goal to reduce fingersticks and bring your patients an advanced algorithm with auto correction bolus.
Bode, B.W., Kaufman, F.R. Pumping Protocol: A Guide to Insulin Pump Therapy Initiation for Insulin-Taking Patients with Type 1 or Type 2 Diabetes. 2nd Edition. 2020 Medtronic MiniMedTM.